Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Cancer Chemotherapy and Pharmacology
|
August 31, 2019
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients
Silpa Nuthalapati, Sven Stodtmann, Stacie Peacock Shepherd, et al.
Clinical Pharmacokinetics
|
December 26, 2022
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, et al.
Journal of Clinical Pharmacology
|
April 17, 2019
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR
Rajendar K Mittapalli, Sven Stodtmann, Anna Friedel, et al.
Journal of Clinical Pharmacology
|
April 11, 2022
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial
Sven Stodtmann, Doerthe Eckert, Rujuta Joshi, et al.
Clinical Pharmacology and Therapeutics
|
July 10, 2024
Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
Sumit Bhatnagar, Louisa Schlachter, Doerthe Eckert, et al.
Clinical and Translational Science
|
February 12, 2024
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, et al.
Journal of Clinical Pharmacology
|
April 24, 2021
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
Sven Stodtmann, Silpa Nuthalapati, Doerthe Eckert, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis
Sven Stodtmann, Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, et al.
Clinical Pharmacology and Therapeutics
|
September 30, 2024
Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient Data
Yuli Qian, Louisa Schlachter, Doerthe Eckert, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease
Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, Sven Stodtmann, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Cancer Chemotherapy and Pharmacology
|
August 31, 2019
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients
Silpa Nuthalapati, Sven Stodtmann, Stacie Peacock Shepherd, et al.
Clinical Pharmacokinetics
|
December 26, 2022
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, et al.
Journal of Clinical Pharmacology
|
April 17, 2019
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR
Rajendar K Mittapalli, Sven Stodtmann, Anna Friedel, et al.
Journal of Clinical Pharmacology
|
April 11, 2022
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial
Sven Stodtmann, Doerthe Eckert, Rujuta Joshi, et al.
Clinical Pharmacology and Therapeutics
|
July 10, 2024
Pharmacokinetics and Exposure-Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
Sumit Bhatnagar, Louisa Schlachter, Doerthe Eckert, et al.
Clinical and Translational Science
|
February 12, 2024
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis
Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, et al.
Journal of Clinical Pharmacology
|
April 24, 2021
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
Sven Stodtmann, Silpa Nuthalapati, Doerthe Eckert, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis
Sven Stodtmann, Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, et al.
Clinical Pharmacology and Therapeutics
|
September 30, 2024
Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient Data
Yuli Qian, Louisa Schlachter, Doerthe Eckert, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease
Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, Sven Stodtmann, et al.
Page
of 3